iShares U.S. Pharmaceuticals ETF $IHE Holdings Lifted by Cadent Capital Advisors LLC

Cadent Capital Advisors LLC increased its holdings in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) by 1,298.7% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,010 shares of the company’s stock after purchasing an additional 32,507 shares during the period. Cadent Capital Advisors LLC owned approximately 0.22% of iShares U.S. Pharmaceuticals ETF worth $3,519,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Hudock Inc. boosted its position in iShares U.S. Pharmaceuticals ETF by 3.9% during the fourth quarter. Hudock Inc. now owns 3,034 shares of the company’s stock valued at $257,000 after buying an additional 114 shares during the period. Sunbelt Securities Inc. lifted its stake in shares of iShares U.S. Pharmaceuticals ETF by 14.3% in the 1st quarter. Sunbelt Securities Inc. now owns 960 shares of the company’s stock valued at $83,000 after acquiring an additional 120 shares during the last quarter. Root Financial Partners LLC boosted its holdings in iShares U.S. Pharmaceuticals ETF by 36.5% during the 1st quarter. Root Financial Partners LLC now owns 696 shares of the company’s stock valued at $60,000 after acquiring an additional 186 shares during the period. Corient Private Wealth LLC grew its position in iShares U.S. Pharmaceuticals ETF by 3.1% during the 4th quarter. Corient Private Wealth LLC now owns 6,506 shares of the company’s stock worth $552,000 after acquiring an additional 198 shares during the last quarter. Finally, Cornerstone Wealth Group LLC increased its stake in iShares U.S. Pharmaceuticals ETF by 13.7% in the 1st quarter. Cornerstone Wealth Group LLC now owns 2,847 shares of the company’s stock worth $246,000 after purchasing an additional 342 shares during the period.

iShares U.S. Pharmaceuticals ETF Trading Up 1.4%

IHE stock traded up $1.37 during midday trading on Friday, hitting $100.23. The company had a trading volume of 109,617 shares, compared to its average volume of 164,446. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of 17.75 and a beta of 0.47. iShares U.S. Pharmaceuticals ETF has a 52 week low of $72.94 and a 52 week high of $108.66. The stock’s 50 day moving average price is $102.73 and its 200 day moving average price is $96.04.

iShares U.S. Pharmaceuticals ETF Profile

(Free Report)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.

Featured Articles

• Five stocks we like better than iShares U.S. Pharmaceuticals ETF
• Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
• Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
• Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
• Arista Networks Plugs Into All-Time Highs

Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).